Pure oestrogen antagonists for the treatment of advanced breast cancer - PubMed (original) (raw)
Review
. 2006 Sep;13(3):689-706.
doi: 10.1677/erc.1.00846.
Affiliations
- PMID: 16954425
- DOI: 10.1677/erc.1.00846
Review
Pure oestrogen antagonists for the treatment of advanced breast cancer
Anthony Howell. Endocr Relat Cancer. 2006 Sep.
Abstract
For more than 30 years, tamoxifen has been the drug of choice in treating patients with oestrogen receptor (ER)-positive breast tumours. However, research has endeavoured to develop agents that match and improve the clinical efficacy of tamoxifen, but lack its partial agonist effects. The first 'pure' oestrogen antagonist was developed in 1987; from this, an even more potent derivative was developed for clinical use, known as fulvestrant (ICI 182,780, 'Faslodex'). Mechanistic studies have shown that fulvestrant possesses high ER-binding affinity and has multiple effects on ER signalling: it blocks dimerisation and nuclear localisation of the ER, reduces cellular levels of ER and blocks ER-mediated gene transcription. Unlike anti-oestrogens chemically related to tamoxifen, fulvestrant also helps circumvent resistance to tamoxifen. There are extensive data to support the lack of partial agonist effects of fulvestrant and, importantly, its lack of cross-resistance with tamoxifen. In phase III studies in patients with locally advanced or metastatic breast cancer, fulvestrant was at least as effective as anastrozole in patients with tamoxifen-resistant tumours, was effective in the first-line setting and was also well tolerated. These data are supported by experience from the compassionate use of fulvestrant in more heavily pretreated patients. Further studies are now underway to determine the best strategy for sequencing oestrogen endocrine therapies and to optimise dosing regimens offulvestrant. At present, and for the foreseeable future, fulvestrant is the only oestrogen antagonist with no agonistic effects licensed for the treatment of advanced breast cancer in postmenopausal women. Other similar oestrogen antagonists are undergoing research and development, with a few currently being evaluated in phase II trials.
Similar articles
- Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective.
Robertson JF. Robertson JF. Cancer Treat Rev. 2004 Dec;30(8):695-706. doi: 10.1016/j.ctrv.2004.04.003. Cancer Treat Rev. 2004. PMID: 15541579 Review. - Preliminary experience with pure antiestrogens.
Howell A. Howell A. Clin Cancer Res. 2001 Dec;7(12 Suppl):4369s-4375s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916227 Review. - Response to fulvestrant in heavily pretreated postmenopausal women: a single-center experience.
Franco S, Perez A, Tan-Chiu E, Frankel C, Vogel CL. Franco S, et al. Breast Cancer Res Treat. 2004 Nov;88(2):103-8. doi: 10.1007/s10549-004-0748-7. Breast Cancer Res Treat. 2004. PMID: 15564793 Clinical Trial. - Fulvestrant ('Faslodex') in heavily pretreated postmenopausal patients with advanced breast cancer: single centre clinical experience from the compassionate use programme.
Mlineritsch B, Psenak O, Mayer P, Moik M, Namberger K, Hauser-Kronberger C, Greil R. Mlineritsch B, et al. Breast Cancer Res Treat. 2007 Nov;106(1):105-12. doi: 10.1007/s10549-006-9482-7. Epub 2007 Feb 13. Breast Cancer Res Treat. 2007. PMID: 17295045 Clinical Trial. - Fulvestrant is an effective and well-tolerated endocrine therapy for postmenopausal women with advanced breast cancer: results from clinical trials.
Vergote I, Robertson JF. Vergote I, et al. Br J Cancer. 2004 Mar;90 Suppl 1(Suppl 1):S11-4. doi: 10.1038/sj.bjc.6601631. Br J Cancer. 2004. PMID: 15094759 Free PMC article. Review.
Cited by
- Antiestrogens: structure-activity relationships and use in breast cancer treatment.
Traboulsi T, El Ezzy M, Gleason JL, Mader S. Traboulsi T, et al. J Mol Endocrinol. 2017 Jan;58(1):R15-R31. doi: 10.1530/JME-16-0024. Epub 2016 Oct 11. J Mol Endocrinol. 2017. PMID: 27729460 Free PMC article. Review. - Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises.
Loechner KJ, McLaughlin JT, Calikoglu AS. Loechner KJ, et al. Int J Pediatr Endocrinol. 2010;2010:670960. doi: 10.1155/2010/670960. Epub 2010 Jun 24. Int J Pediatr Endocrinol. 2010. PMID: 20652035 Free PMC article. - Differential dependency network analysis to identify condition-specific topological changes in biological networks.
Zhang B, Li H, Riggins RB, Zhan M, Xuan J, Zhang Z, Hoffman EP, Clarke R, Wang Y. Zhang B, et al. Bioinformatics. 2009 Feb 15;25(4):526-32. doi: 10.1093/bioinformatics/btn660. Epub 2008 Dec 26. Bioinformatics. 2009. PMID: 19112081 Free PMC article. - Parallel factor ChIP provides essential internal control for quantitative differential ChIP-seq.
Guertin MJ, Cullen AE, Markowetz F, Holding AN. Guertin MJ, et al. Nucleic Acids Res. 2018 Jul 6;46(12):e75. doi: 10.1093/nar/gky252. Nucleic Acids Res. 2018. PMID: 29672735 Free PMC article. - Estrogen inhibits ATR signaling to cell cycle checkpoints and DNA repair.
Pedram A, Razandi M, Evinger AJ, Lee E, Levin ER. Pedram A, et al. Mol Biol Cell. 2009 Jul;20(14):3374-89. doi: 10.1091/mbc.e09-01-0085. Epub 2009 May 28. Mol Biol Cell. 2009. PMID: 19477925 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical